Fidaxomicin for the Treatment of <i>Clostridioides difficile</i> Infection in Adult Patients: An Update on Results from Randomized Controlled Trials

• 主要な著者: Daniele Roberto Giacobbe (著者), Antonio Vena (著者), Marco Falcone (著者), Francesco Menichetti (著者), Matteo Bassetti (著者)
• フォーマット: 図書
• 出版事項: MDPI AG, 2022-10-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

In recently updated international guidelines, fidaxomicin is preferentially recommended as first-line treatment over vancomycin both for the first episode of CDI and for rCDI, based on the results of different randomized controlled trials (RCTs). Although noninferiority was the rule in phase-3 RCTs...